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Abstract
Introduction: Scleroderma, also known as systemic sclerosis, is a rare, complex and 
autoimmune disease, with unknown origin and cause (Coelho, Oliveira, & Kroon, 2008). It 
affects the connective tissue and is characterized by vascular dysfunction, inflammatory and 
fibrotic of multiple organ systems (Nadashkevich, Davis, &Fritzer, 2004). The symptoms that 
suggest the existence of scleroderma include: Raynaud phenomenon, skin thickening, 
calcinosis and telangiectasia (Li, Sahhar, & Littlejohn, 2008). In addition to the swelling of the 
fingers and hands that may hinder mobility and become a very painful phenomenon (Li et al, 
2008), the alterations in internal organs results in significant morbidity and mortality (Assassi, 
del Junco, Sutter, McNearney, Reveille, Karvanas, …,Gourh, 2009). Despite its severity, the 
disease remains unknown to many health professionals and may take several years before 
those affected are diagnosed. This disease is associated with pain, fatigue and progressive 
disability. Among the physical changes with more psychological impact are the changes in 
the skin (Malcarne, Hansdottir, Greenbergs, Clements & Weisman, 1999). Due to the 
disfigurement and physical changes that are typical of the disease, psychological morbidity is 
high and includes depression, body image problems.
Method: The participants in this study are 563 scleroderma patients from 12 European 
countries and Brazil. These participants are mostly women. The instruments used in this 
study were the “Canadian Scleroderma Patient Survey of Health Concerns and Research 
Priorities” and “The Brief Illness Perception Questionnaire (Brief IPQ)”.
Results: The most common symptoms and with more impact on the lives of the participants 
were joint pain, fatigue and Raynaud’s. Just under one fifth of the participants had a 
diagnosis of scleroderma with the first doctor consulted. Participants with more years of 
diagnosis revealed to be more satisfied with the medical care they receive. Participants 
reported a high degree of concern with scleroderma and 84% reported concerns with body 
image due scleroderma. Depression, anxiety and social phobia are common among 
scleroderma patients.  
Conclusion: Due to gravity, lack of knowledge, unpredictability and disfigurement of 
scleroderma, the existence of psychological disorders in these patients is common.
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Introduction
Chronic diseases are the greatest cause of morbidity and mortality, and their 
diagnosis is, in most cases, a period of uncertainty, doubt and general crisis. Besides the 
physical well being, the patient also suffers psychological, social and functional changes 
which, as several studies show, present an increased possibility of anxiety and depression 
(Beutel & Schulz, 2011).
Scleroderma
Scleroderma is an autoimmune, connective tissue disease characterized by fibrosis, 
degenerative changes and vascular lesions in the skin, joints, and multiple internal organs 
(Nadashkevich et al, 2004). The disease may impair the proper functioning of respiratory, 
gastrointestinal, and cardiac systems and renal function, which leads to a significant 
incidence of morbidity and mortality (Li et al, 2008). Scleroderma is also characterized 
fibroblast activation, collagen overproduction, and pathological tissue fibrosis (Varga, 2008). 
The diagnosis, prognosis and treatment can be very difficult (Ruzek, Jha, Ledbetter, 
Richards & Garman, 2004). Scleroderma is a heterogeneous, but serious, disease of 
unknown cause (Coelho et al, 2008), where lung abnormalities are the leading cause of 
death (Gupta& Thabah, 2007). The two primary lung manifestations disease are interstitial 
lung disease and pulmonary vascular disease (Roth, Tseng, Clements, Furst, Tashkin, 
Goldin, … Elashoff, 2011). Patients with respiratory symptoms can have chronic aspiration, 
airway disease, neuromuscular weakness, extrinsic restriction secondary to a hide-bound 
chest, pleural effusions and lung cancer, and all of this cause clinically significant disease (Le 
Pavec, Launay, Mathai, Hassoun & Humbert, 2011). The organ system most frequently 
affected with scleroderma is the gastrointestinal tract (Plastiras, Tzivras &
Vlachoyiannopoulos, 2007). The esophageal muscle weakness and incoordination can 
impair intake of solid aliments. With the malfunctioning of the lower esophageal sphincter 
esophageal reflux occurs what causes heartburn, a very common symptom in people with 
scleroderma. The commitment of the small intestine can be affected causing pain, 
hypomobility intestinal bloating, diarrhea, malabsorption and weight loss. The large intestine 
affectation can cause constipation (Christmann & Silver, 2010). Gastrointestinal involvement 
can be also debilitating and even life threatening (Plastiras et al, 2007). Cardiac involvement 
is common in scleroderma; the diagnosis is not always clear or may be associated with left 
ventricular diastolic dysfunction. The commitment of the heart may be due to cardiac fibrosis 
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and not just pulmonary arterial hypertension (Varga, 2008). The renal crisis in scleroderma 
may be caused by lesions in the arteries of medium size. These injuries can also 
causehyperreninemia with malignant hypertension, microangiopathic hemolytic anemia, and 
rapidly progressive renal failure (Varga, 2008). 15% of people suffer from scleroderma renal 
crisis; such crises develop mainly in the first 4 years of diagnosis (Varga, 2008). 
The first symptoms of scleroderma are usually the appearance of Raynaud's 
phenomenon and skin changes typical of the disease (Vilella, Aznar & Julià, 2010). These 
usually occur on the hands and may also affect the arms, face, trunk, and legs. 
Scleroderma means hard skin. With scleroderma skin loses elasticity and becomes 
harder. After initial hardening, the dermis is left with excess collagen and thus, beyond
getting hard, it is also thicker (Kissin, Schiller, Gelbard, Anderson, Falanga, Simms, … 
Merkel, 2006). The greater involvement of the skin, the less is the chances of survival
(Clements, Lachenbruch, Simmons, Sterz,& Furst, 1990). Thus, skin thickening is the 
hallmark of scleroderma, and its severity and extent is a way to differentiate the kind and
severity of scleroderma (Steen & Medsger, 2001). The first skin changes are characterized 
by skin thickening and swelling. After this phase, the skin becomes firm and connected to the 
subcutaneous tissue, which may cause flexion contractures, limiting movement. Finally, the 
skin becomes thinner, which facilitates the appearance of ulcers and infections. In the face, 
lips become thinner; there is a reduction in the amplitude of mouth opening, loss of natural 
skin wrinkles and facial expression lines (Li et al, 2008). The reduction of mouth opening 
calls microstomia, this problem can reduce quality of life, because interferes with eating,
brushing teeth and dental care (Pizzo, Scardina,& Messina, 2003). 
Raynaud’s phenomenon may be described by digital artery vasospasm. These 
episodic clinical attacks occur mainly in the fingers (Brown, Middaugh, Haythornthwaite,& 
Bielory, 2001). The Raynaud's phenomenon is present in more than 95% of patients with 
scleroderma and usually precedes the appearance of scleroderma for several years (Merkel,
Herlyn, Martin, Anderson, Mayes, Bell & Wigley, 2002). Thus Raynaud's phenomenon offers 
the best window for research of first steps in the pathogenesis of scleroderma (Kahaleh, 
2004). This phenomenon is characterized by episodes of sudden, transient and recurrent 
changes in the fingers, caused by exposure to cold or emotional stress (Hinchcliff & Varga,
2008). Thus, the fingers turn white (vasospasm), then moving to a blue-violet hue (ischemia) 
and finally turn red (hyperemia) (Hinchcliff& Varga, 2008). Normally we can observe painful 
ulcers that can be very limiting for most of the movements and may be necessary to 
amputate part of fingers. Raynaud's phenomenon has a great impact in quality of life and 
functioning of patients with scleroderma, this impact varies with  the frequency, duration and 
severity of attacks, with the presence and activity of digital ulcers, and with other problems 
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related with scleroderma such as hardening skin, pain, shortness of breath and functional 
disability (Merkel et al, 2002). Digital ulcers are necrotic lesions at the fingertips. 50% of 
people with diffuse or limited scleroderma, have digital ulcers (Chung& Fiorentino, 2006).
Erectile dysfunction in men with scleroderma is common. Several studies suggest 
that erectile dysfunction associated with scleroderma is due to the damage of blood vessels 
and fibrotic changes (Ostojic& Damjanov, 2007). In turn, women with scleroderma are more 
likely to suffer from dyspareunia, vaginal dryness and vaginal ulcers compared with women 
with other rheumatic diseases (Knafo, Jewett, Bassel & Thombs, 2010). Despite these 
physical changes, according Knafo et al (2010) is necessary to determine which 
psychosocial characteristics of the disease can contribute to sexual dysfunction.
In addition to other symptoms, patients often suffer from a wide range of musculo-
skeletal disorders such as joint pain, arthritis, flexion contractures of the joints and muscle 
weakness (Ostojic, Zivojinovic, Reza & Damjanov, 2010). In some patients with scleroderma 
the skeletal mucles alterations may range from mild to severe, few patients develop a 
debilitating or even life-threatening course (Olsen, King & Park, 1996).
Types of Scleroderma
Scleroderma is divided into three types: limited, diffuse and systemic sclerosis sine 
scleroderma.The most common types of Scleroderma are limited scleroderma and diffuse 
scleroderma (Hinchcliff& Varga, 2008). These types vary in the extension of damaged skin, 
and in relation to the organs affected (Li et al, 2008). 
The most common is limited scleroderma, which affects approximately 60% of people 
with scleroderma. CREST syndrome is a variant of this type of scleroderma(Hinchcliff& 
Varga, 2008). The meaning of the acronym CREST: calcinosis, Raynaud's phenomenon, 
esophageal dysmotility, sclerodactyly (tension in the skin of the fingers, which can hinder or 
even prevent the mobility of the fingers and create contractures) and telangiectasia (dilation 
of blood vessels in the outer layer of skin) (Li et al, 2008). 
The diffuse scleroderma affects about 35% of people with scleroderma (Hinchcliff& 
Varga, 2008). People with this type are more likely to develop pulmonary interstitial disease 
and heart or kidney disease in an early stage of the disease (Li et al, 2008). Finally, systemic 
sclerosis sine scleroderma is the least common, affecting only 5% of people with this disease 
and manifests itself unaccompanied by changes in the skin, including skin thickening
(Hinchcliff& Varga, 2008). It is considered that a patient has systemic sclerosis sine 
scleroderma if he or she has all of these assumptions: Raynaud’s, positive ANA (anti-nuclear 
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antibody) and one of the following: distal esophageal hypomotility, small bowel hypomotility, 
pulmonary interstitial fibrosis, primary pulmonary arterial hypertension, cardiac involvement 
or renal crisis (Poormoghim, Lucas, Fertig & Medsger, 2000).
The localized forms of the disease are morphea and linear scleroderma. Limited 
scleroderma or morphea is characterized by a thickening of the skin with increased collagen 
deposition (Zulian, Athreya, Laxer, Nelson, de Oliveira, Punaro, … Harper, 2006). Linear 
scleroderma is characterized by scleroatrophic lesions that affects asymmetrically arms and 
legs (Grosso, Fioravante, Biasi, Conversano, Marcolongo, Morgese & Balestri, 2003).Linear 
scleroderma is the most common type of localized scleroderma in children and adolescents 
and is characterized by the appearance of one or more strips, usually on the upper or lower 
limbs, and may be associated with plaques of morphea. When one of these linear lesions 
affect the face or scalp is called scleroderma en coup de sabre, a subtype of linear 
scleroderma (Kasapçopur, Ozkan & Tuysuz, 2003). The different form of localized 
scleroderma affects mainly children and is not associated with Raynaud's phenomenon or 
significant visceral manifestations (Hinchcliff& Varga, 2008).
Prevalence
The prevalence of this disease is 30 per 100,000 people (Chifflot, Fautrel, Sordet, 
Chatelus & Sibilia, 2008), with a proportion of four women for every man affected, especially 
over 40 years old. In Portugal, there is no actual data about the number of people diagnosed 
with scleroderma, but it is estimated that there are over 3,000 people, attending the studies
of scleroderma’s prevalence.
Impact of Scleroderma
Scleroderma has a physical, psychological and socialimpact.
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Physical impact
Fatigue is considered one of the symptoms of greater impact among patients 
(Taillefer, Bernstein, Schieir, Buzza, Hudson, Scleroderma Society of Canada, … Thombs, 
2010), independently of the scleroderma type (Morell-Dubois, Condette-Wojtasik, Clerson, 
Berezné, Launay, Lambert, ... Hachulla, 2011).In terms of physical impact, fatigue is often 
considered by people with chronic diseases such as the symptom that most affect their 
quality of life (Swain, 2000), being a symptom that includes complex interactions between 
biological, psychosocial and behavioral processes. According to Swain (2000), persistent 
fatigue in chronic disease involves continuing tiredness disproportionate to the effort made 
and that is not relieved by rest.It is a common and incapacitating symptom related with 
precarious sleeping quality, greater pain, depressive symptoms and a deficit in physical and 
social functioning (Sandusky, McGuire, Smith, Wigley & Haythornthwaite, 2009). Fatigue is 
defined as the experience of feeling weak, tired and lacking energy. In scleroderma, this is 
similar to that of patients who are receiving treatment for cancer (Thombs, Fuss, Hudson, 
Schieir, Taillefer, Fogel, … Canadian Scleroderma Research Group, 2008).  
Experiencing difficulties when trying to sleep is also one of the symptoms that affect 
patients more severely (Taillefer et al, 2010). Patients’ sleep can be interrupted by 
gastroesophageal reflux disease, pulmonary fibrosis with dyspnea and the restless legs 
symptom (Abad, Sarinas & Guilleminault, 2008), which reduces sleep efficiency.
Pain is common among patients with scleroderma (Benrud-Larson, Haythornthwaite, 
Heinberg, Boling, Reed, White & Wigley, 2002). Painful symptoms are associated with the 
frequency of Raynaud's phenomenon, digital ulcers, joint pain and gastrointestinal symptoms 
(Morell-Dubois et al, 2011). Digital Ulcers are extremely painful and cause significant 
functional disability (Chung& Fiorentino, 2006). The pain is crucial in physical functioning and 
social adaptation, both relevant factors in quality of life (Benrud-Larson et al, 2002). 
Psychological impact
Psychological factors with confirmed relevance to scleroderma include pain, 
depression, and distress about disfigurement, and physical and social function 
(Haythornthwaite, Heinberg & McGuire, 2003).
Scleroderma affects body image and is associated with depressive and anxiety 
symptoms and sexual dysfunction. Many rheumatic diseases (scleroderma is part of this 
group) involves visible physical changes associated with disease progression (Malcarne et 
Psychosocial Characterization, Symptoms and Illness Perception in Scleroderma Patients: 
an international study
12
al, 1999). However, while in other types of diseases the changes remains, in scleroderma 
these alters over time and tend to worsen (Taillefer et al, 2010), existing facial disfigurement 
and usually hands disfigurement.
These physical disfiguring changes are in visible and important interpersonal contact 
body parts. From the beginning, scleroderma causes significant physical changes, such as 
swelling of fingers, loss of natural skin wrinkles, the change on the skin for brighter, hypo-or 
hyper-pigmentation of the skin, facial changes at as the loss of flexibility in the lips, loss of 
ability to fully open the mouth, difficulty in completely close the lips and changes in the 
appearance of the eyes and nose (Malcarne et al, 1999). Age and disability are associated 
with dissatisfaction with body image, and younger patients with severe symptoms of the 
disease have an increased risk of developing body image concerns (Benrud-Larson,
Heinberg, Boling, Reed, White, Wigley & Haythornthwaite, 2003). The results of the 
"Canadian Scleroderma Patient Survey of Health Concerns and Research Priorities" show 
that 77% of participants reveal concern about their physical appearance due to scleroderma, 
related to the hands and / or face (Taillefer et al, 2010).
In terms of depressive symptoms, the same Canadian study showed that about half 
of the participants report feeling "down, depressed or hopeless" at least several days in the 
previous two weeks.
The manifestation of depressive symptoms is favored in people with rheumatic 
diseases (Kobayashi-Gutiérrez,Martinez-Bonilla, Bernard-Medina, Troyo-Sanroman, 
González-Díaz, Castro-Contreras, ... Torres-Mendoza, 2009), and a frequent complication in 
scleroderma (Benrud-Larson et al, 2002). The symptoms of scleroderma can be painful, such 
as digital ulcers, Raynaud's phenomenon, skin changes, joint contractures and 
gastroesophageal reflux (Benrud-Larson et al, 2002), and severity of symptoms of pain is 
associated with depression (Kobayashi-Gutiérrez et al, 2009). In addition to pain, feelings of 
shame, disgust of themselves and self-deprecation of the body, are factors contributing to 
the adjustment to disease (Richards, Herrick, Griffin, Gwilliam & Fortune, 2004) and provide 
depressive symptoms (Roca, Wigley & White, 1996). On the other hand lowsocial support is 
one factor that predisposes to depression in these patients (Legendre, Allanore, Ferrand & 
Kahan, 2005). These symptoms of depression are in turn associated with an impairment of 
vocational, social and sexual adjustment (Benrud-Larson et al, 2002), directly affecting the 
quality of life (Danieli, Airò, Bettoni, Cinquini, Antonioli, Cavazzana, … Cattaneo, 2005).
The few studies conducted with these patients suggest that the quality of life is 
significantly diminished, and that half of patients with scleroderma are depressed. 
Depression symptoms have a considerable negative impact on clinical outcomes. Studies on 
women with scleroderma (females are more affected by the disease) suggest that these 
Psychosocial Characterization, Symptoms and Illness Perception in Scleroderma Patients: 
an international study
13
patients show a high degree of dissatisfaction with body image, with depression being a 
moderating variable between dissatisfaction with body image and psychosocial function 
(Benrud-Larson et al, 2003). 
In addition to depression, anxiety is also common in patients with scleroderma 
(Legendre et al, 2005). Anxiety symptoms are associated with clinical pain and changes in
quality of life (Baubet, Ranque, Taïeb, Bérezné, Bricou, Mehallel, … Mouton, 2011) these 
symptoms are predicted by cognitive factors in relation to fear of negative evaluation 
(Richards et al, 2004). 
The physical and psychological symptoms, including concerns about body image and 
depressive symptoms may have an impact on sexual functioning of patients with 
scleroderma (Thombs, Jewett, Assassi, Baron, Maia, El-Baalbaki, … Khanna, in press), of 
which women with scleroderma have greater commitment and sexual distress (Knafo, 2010). 
Social Impact
Due to the high physical and psychological morbidity, social impact of this disease 
can be observed in the social costs associated with it. In addition to the costs associated with 
high use of health care with long periods of morbidity (Hansdottir, Malcarne, Furst, 
Weissman & Clements, 2004), the "Canadian Scleroderma Patient Survey of Health 
Concerns and Research Priorities" shows that half of the participants who were working 
indicated that the scleroderma affect their ability to perform their functions at work and one 
quarter of the participants also noted that scleroderma have an economic impact in their 
lives(Taillefer et al, 2010). This study also suggests that patients with scleroderma are more 
dissatisfied with health care than other chronically ill patients.
In the same study, almost half of participants reported that scleroderma affects very 
much or extremely, their capacity to work. More than half of participants reported that there 
was little to no understanding by their workplace of how their medical situation affected their 
capacity to work. Work disability constitutes a serious problem to scleroderma patients and 
this problem is associated with pain, fatigue and impaired hand function (Sandqvist, Scheja & 
Hesselstrand, 2010). 
Psychosocial Characterization, Symptoms and Illness Perception in Scleroderma Patients: 
an international study
14
Illness perception
Patients with chronic illnesses often have an array of difficulties that may vary, 
depending of their concept about their disease, especially perceived severity and the type of 
development and control the person perceives. The illness representation that the patient 
creates is based on the information that he may have received from his doctors; and 
information from family and friends (Richards, Herrick, Griffin, Gwilliam, Loukes & Fortune,
2003). The literature reviewed allowed to locate only one study (carried out with only 49
participants) on the perception of the disease in scleroderma, showing that illness perception 
is related to emotional disturbance (Richards et al, 2003).This study also found that about 
half of the people with scleroderma do not understand the disease, making adjustment a 
difficult task, since people who have a good understanding are more likely to distance 
themselves emotionally, giving them a greater sense of control.
Intervention
Once scleroderma is a heterogeneous disease, treatment should be adapted to the 
needs of each patient (Hinchcliff& Varga, 2008). In addition to the medical treatment of 
symptoms of the disease, and considering all the implications of physical, psychological and 
social causes of the scleroderma, the psychological support is essential.
At present it is acknowledged that the treatment offered to these patients is not 
sufficient and an international team of researchers, health professionals and 
patients(Thombs et al., in press), are developing an intervention program for patients with 
scleroderma (The Scleroderma Patient-Centered Intervention Network - SPIN). This group is 
composed of representatives of patient organizations in Canada, the United States and 
Europe, doctors and researchers with expertise in this pathology, and researchers with 
expertise in health services research, health economics, health technology assessment, 
health policy and utilization of technology to provide health services to patients. The aim of 
the group, based on priority needs identified for these patients, respond to major problems: 
improving the functioning of the hands, reducing depressive symptoms, treat concerns about 
body image, and implement a general self-management oriented to the needs of patients 
(Thombs et al, in press). As the authors affirm, the creation of this group and putting into 
practice of his proposals will help to fill the gap in psychosocial research of scleroderma and 
also in clinical practice, providing the development and testing of intervention models, 
accessible to a large number of people with scleroderma.
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It is estimated that there are more than 3,000 patients in Portugal. However, so far 
there has been no attempt to do a symptomatic characterization, or a study on the illness 
perception, the psychological and social impact of the disorder. The results of Canadian 
study showed several disturbing signs that reveal the needs for action in this area. On the 
European scene, there are few studies and, due to the absence of a psychosocial 
characterization, it is not possible to define the priority areas of intervention.This study aims 
to fill this gap, andallow patients with scleroderma expose the symptoms that most affect 
their life, how they feel about the disease and the perception of threat they feel about it.
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Empirical study
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The main objectives of this study were:
(1) To characterize the main symptoms of the disease and their impact on the quality of 
life among scleroderma patients;
(2) To assess the way that patients evaluate their satisfaction with medical care in terms 
of general satisfaction, technical quality, interpersonal manner, communication, 
financial aspects, time spent with doctor and accessibility and convenience.
(3) To describe the psychological symptoms, specially depressive symptoms;
(4) To assess the impact of physical appearance on social functioning;
(5) To understand the illness perception in terms of consequences, timeline, personal 
control, identity, coherence, emotional representation andillness concern.
(6) To evaluate the impact of the symptoms of the disease and illness perception on 
physical appearance
With this research we want to promote research on scleroderma calling attention to 
the various realities of the disease and raise awareness among health professionals 
and the general public to this problem. More specifically, to inform health 
professionals so that they can provide health care, more aware of the psychological 
reality of scleroderma.
Method
Participants
This study has 563 participants belonging to various European countries and Brazil. 
The European countries involved in the study are:France, United Kingdom, Cyprus, Hungary, 
Poland, Ireland, Finland, Denmark, Norway, Portugal, Spain and Italy. Data was collected 
between December 2010 and July 2011. 
The criterion for participation in this study was that the participants need to have 
scleroderma. Participation was voluntary.
The mean age of participants were 47 years old (SD=14.1) and they were mostly 
female (N=490, 89%). Most of the participants were white (N= 511, 93%) and married or 
living as married (N= 373, 68%). Only 12% (N= 65) of the participants live alone and most 
participants have a college degree (N= 180, 37%). 34% (184) of participants reported that 
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were disable, on sick leave or unemployed, of those 184 participants, 108 (59%) have also 
reported that scleroderma was the reason. 
Table 1
Demographics of participants
Frequency Percent
Gender:
Female 490 88.9
Male 61 11.1
Racial/Ethnic Background:
White 511 93.2
Black 16 2.9
Other 20 3.6
Current Marital Status
Single 89 16.3
Married or living as married 373 68.3
Separated 25 4.6
Divorced 48 8.8
Widowed 11 2
Current family dwelling composition
Alone 65 12.4
Living with spouse/partner 210 40.2
Living with spouse/partner and children 151 28.9
Living with children, no spouse/partner 29 5.5
Living with friends 5 1
Other 4 .8
Highest level of education
Primary school 45 9.2
Secondary school 71 14.4
Higher education 157 32
University 180 36.7
Master 24 4.9
PhD 13 2.6
Current employment status
Working full-time 145 26.7
Working part-time 54 9.6
Homemaker 37 6.8
Student 26 4.8
Retired 98 18
Disabled, sick leave or unemployed 184 33.8
If Yes --» because of scleroderma 108 58.7
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Instruments
Canadian Scleroderma Patient Survey of Health Concerns and Research Priorities 
(Scleroderma Society of Canada and Canadian Scleroderma Research Group) was given to 
us by the authors with the proper authorization to translate. The authors created this 
questionnaire in order to access the most important aspects of living with scleroderma.To 
prepare for this questionnaire the team studied the existing literature and questionnaires 
about scleroderma and other rheumatic diseases.
The questionnaire has 11 Sections (Demographics; Diagnosis and Disease; 
Healthcare Services Utilization; Healthcare Services Reimbursement; Healthcare Services 
Reimbursement Needs;  Medical Care; Symptoms; Employment; Sensations; Physical 
Appearance; Commentaries). 
Section A (Demographics) is based on “Arthritis Treatment and Care in Canada 
Survey”.The Section B (Diagnosis and Disease)aims to describe the medical status of 
participants, such as determining the type of scleroderma and other health problems. Section 
C (Healthcare Services Utilization)aims to make a list of health services most often used by 
patients with scleroderma and also approach issues concerning mental health. Section D 
(Healthcare Services Reimbursement) andSection E (Healthcare Services Reimbursement 
Needs) will not be included in this study because health systems are different in the various 
countries that constitute this study. Section F (Medical Care) aims to assess what people 
with scleroderma feel about the medical care provided to them.This section uses an existing 
survey:The Patient Satisfaction Questionnaire Short-Form(Marshall & Hays, 1994). Section 
G (Symptoms) aims to list the frequency and impact of 69 symptoms. This section is based 
on The Scleroderma Assessment Questionnaire (SAQ)(Ostojic& Damjanov, 2006) and 
several articles. Section H (Employment) aims concerns about employment. Section I 
(Sensations) assesses depression, anxiety and social phobia. Depression is assessed with 
the instrument The PHQ-2 a new depression diagnostic and severity measure(Kroenke & 
Spitzer, 2002). The cut-off of this two items instrument is three, higher than or equal to three 
means sensitivity to severe depression. The first item assesses anhedonia and the second 
item assesses dysphoria. The sum of two items is a maximum of 6. Anxiety is assessed with 
the instrument Generalized Anxiety Disorder (GAD)(Kroenke, Spitzer, Williams, Monahan,& 
Lowe, 2007) and includes two items. The cut off this two items instrument is three, higher 
than or equal to three means generalized anxiety disorder. The sum of two items is a 
maximum of 6.Finally, social phobia is evaluated with the instrumentMini SPIN: a brief 
screening assessment for generalized social anxiety disorder (Connor, Kobak, Churchill, 
Katzelnick,& Davidson, 2001). The cut off the items of this instrument is six. Higher than or 
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equal to six means general social anxiety disorder. The sum of items varies between zero 
and a maximum of twelve. Section J (Physical Appearance) aims to assess concerns about 
body image.The three questions in this section are from the instrumentThe Body Image 
Disturbance Questionnaire (Cash, Phillips, Santos,& Hrabosky, 2004).Finally, the last section 
called "Commentary" is an open question that allows participants to write about something 
they think is relevant and has not been covered in the questionnaire.
The Brief Illness Perception Questionnaire (Brief IPQ)(Broadbent, Petrie, Main & Weinman, 
2006), in existing versions in several languages (see“http://www.uib.no/ipq/”). This
Questionnaire has nine items and assesses nine dimensions of illness perceptions, one per 
item. The dimensions assessed are: consequences, timeline, personal control, treatment 
control, identity, coherence, emotional representation, concern and causal attributions. The 
dimensions are evaluated quantitatively. A high score on the dimensions "consequences" 
and "timeline" means a more negative and more chronic illness perception, respectively. In 
the dimensions “personal control” and “treatment control”, the higher the score represents 
more control. A high result in the dimension "identity" means that the participant associates a 
high number of symptoms to the illness.In turn, a high result in the dimension "coherence" 
reflects a poor understanding about the illness.In the "emotional representation" a high score 
means that the participant has negative emotions regarding the illness.In the "concern" the 
result reflect the level of concern about the illness; the higher result is equivalent to greater 
concern.The compute of the first eight items also allow evaluating the perception of threat in 
relation to illness. Highest score reflect greater perceived threat.
Procedure
After the contact with the Canadian team, we contacted the Federation of European 
Scleroderma Associations (FESCA) and all the European associations of scleroderma and 
all accepted to collaborate with the study. 
The various associations have issued the study in several ways: sharing the details 
on their webpage, writing an advertisement in their newsletters and sending information to 
the email addresses of patients.
In Portugal, besides the support of the Portuguese Association of Patients with 
Scleroderma (APDE), we contacted all 50 hospitals treating patients with this condition.After 
the first contact we have submitted the project to the respective ethics committees. We 
obtained positive responses from all major national hospitals who are dealing with this 
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pathology.We got in contact with several doctors who treat patients with scleroderma and 
asked collaboration to disseminate the study to their patients. At the Hospital of S. João
(Porto) it has been possible to collect data directly with patients. In the remainder, some had 
the collaboration of doctors who gave the questionnaires and helped to fill, in other cases, 
doctorsshared the questionnaire’s link with the patients so that they would go online and fill it 
out.
For Brazil, we contacted the Association of Brazilian Patients with Scleroderma 
(ABRAPES). 
Two methods were used in order to reach as many patients as we can and to get 
them to fill out the survey: 
(1) We used Survey Monkey to create online versions of the survey. For each country we 
have created a different link. 
(2) We also printed out on paper to provide the survey to patients who had no Internet 
access.
Confidentiality and anonymity were guaranteed either the online version or paper 
version of the questionnaire. In both versions were not asked the participants’ names, date of 
birth, telephone number, and anything that would allowthe participants’ identification.
To perform this study we had to translate the questionnaire to several languages. The 
Canadian team has provided us the version of the questionnaire in English and French. To 
cover a larger number of countries was necessary to translate the questionnaire into other 
languages. The languages chosen were: Danish, Portuguese, Spanish, Italian and 
German.The translation into Danish and German were made by the associations of 
scleroderma patients from Denmark and Belgium, respectively. Regardless of the language, 
some questions of the questionnaires (e.g. educational level) were adapted for each country.
Procedure for Data Analysis
The data analysis, descriptive and inferential, was performed using the statistical 
software package SPSS 18 (for Windows). 
We did the exploratory data analysis to verify if the normality and homogeneity of the 
variables was guaranteed, which did not happen. However, we chose to do both tests, 
parametric and nonparametric, the results were equivalent, so we chose to present the 
results of parametric tests, since they are more robust (cf. Martins, 2011, p. 240).
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We use descriptive statistics to describe the data. To make inferences from the data 
to general conditions, we used inferential statistics.In analyzing the results the differences 
are considered significant if p <.05.
Results
Diagnosis and Disease
In this section we summarize diagnosis and disease information. The Table 2 refers 
diagnosis information. Most of participants reported having been diagnosed with Diffuse 
Scleroderma or CREST. Rheumatology is the medical specialty most reported regarding the 
diagnosis of scleroderma.
The participants were diagnosed between 1 and 56 years ago (mean =8.45 ((SD = 
7.21)). Only 19% (N=94) of participants got the diagnosis with the first doctor. However, 17% 
(N=86) were obliged to consult more than five physicians for diagnosis.
The information about Raynaud's indicates that 455 participants (91%) reported 
having Raynaud’s.
Table 2
Diagnosis Information
Frequency Percent
Type of scleroderma:
Limited 80 16.1
Diffuse 145 29.1
CREST 104 20.9
SINE 8 1.6
Linear 17 3.4
Morphea 22 4.4
Systemic 71 14.3
Unknown 49 9.8
Who diagnose
Rheumatologist 265 53.6
Family doctor 45 9.1
Dermatologist 89 18
Internist 59 11.9
Pneumologist 7 1.4
Other 29 5.9
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Table 3 lists all other medical conditions reported. Most of participants reported at 
least one other medical conditions (73%). The most conditions reported are esophageal 
dysfunction, pain, lung disease, osteoarthritis and depression. 
Table 3
Other Medical Conditions
Frequency Percent
Esophageal dysfunction 199 35.3
Pain 123 21.8
Lung disease 115 20.4
Osteoarthritis 110 19.5
Depression 97 17.2
Ulcer or Stomach disease 76 13.5
High blood pressure 61 10.8
Rheumatoid Arthritis 56 9.9
Fibromyalgia 48 8.5
Heart disease 19 3.4
Diabetes 19 3.4
Hearing problems 35 6.2
Anemia 13 2.3
Kidney disease 11 2
Lupus 10 1.8
Cancer 6 1.1
Other 162 28.8
Healthcare Services Utilization
More than a half percent of participants (53%) were hospitalized at least once in the 
past because of scleroderma symptoms and 38% of the participants reported having access 
to adequate mental health care. However 65% never participated in support groups and the 
reason most often mentioned (48%) is that none is easily available.
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Healthcare Services Reimbursement Needs
Table 4 contains the information about the health care services that the participants 
think considered necessary but were not receiving because of the cost. No more than one 
third of the participants reported that there were healthcare services they needed that they 
were not receiving because of the cost. The most often health services that participants 
reported they needed but were not receiving due to this reason were physiotherapy, vitamins 
and/or supplements, massage therapy, exercise therapy, and prescribed medicaments. 
Table 4
Need for health care
Frequency Percent
None 178 32
Osteopathy 19 3
Post-surgical homecare 1 0
Personal care attendant services 4 1
Prescription medicaments 73 13
Non-prescription medicaments 47 8
Exercise therapy 93 17
Chiropractic therapy 9 2
Occupational therapy 6 1
Physiotherapy 116 21
Massage therapy 94 17
Acupuncture 70 12
Naturopathy 9 2
Vitamins and/or supplements 98 17
Assistive devices 6 1
Meal preparation aid services 34 6
Transportation 14 3
Personal care attendant services 3 1
House cleaning services 8 1
Bandages, ointments, and creams 60 11
Other 20 4
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Medical Care
Table 5 summarizes the level of satisfaction of the participants with the medical care 
they are receiving with respect to seven domains: general satisfaction, technical quality of 
care, interpersonal manner, communication, financial aspects, time spent with physician, 
accessibility and convenience of care. Response options ranged from 1 (agree strongly) to 5 
(strongly disagree). Some questions wore recoded so that for all items, higher scores 
represented higher satisfaction with medical care. In general, participants reflect to have 
positive attitudes regarding the medical care provided to them.The area where they are less 
satisfied is with the time spent with the doctor, and they show greater satisfaction with the 
interpersonal manner. 
Table 5
Mean and standard deviation of Satisfaction with medical care
Satisfaction with 
Medical Care
General Satisfaction 3.2 (1.03)
Medical care about perfect 3.25 (1.07)
Dissatisfaction with some things about medical care 3.16 (1.3)
Technical Quality of Care 3.35 (0.86)
Doctor’s office has everything to provide complete care 3.2 (1.21)
Doubts about doctor diagnosis 2.89 (1.23)
Doctor are careful to check everything in the treatment 3.45 (1.1)
Doubts about the ability of doctors 3.34 (1.24)
Interpersonal Manner 3.62 (0.94)
Doctors act too businesslike and impersonal toward 3.3 (1.21)
Doctors treat in a very friendly and courteous manner 3.99 (0.98)
Communication 3.2 (0.98)
Doctors are good explaining the reason for medical tests 3.57 (1.09)
Doctors sometimes act ignoring 2.88 (1.19)
Financial Aspects 3.18 (1.08)
Confidence in being able to obtain medical care without financial 
loss
3.23 (1.19)
Prices of medical care is above the economic possibilities 3.21 (1.28)
Time Spent with Physician 3.14 (0.85)
Treatments are done in a hurry 2.82 (1.06)
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Doctors spend plenty time in attendance 3.49 (1.1)
Accessibility and Convenience 3.19 (0.8)
Easy access to medical specialists required 3.54 (1.16)
People have to wait too long for emergency treatment 2.97 (1.13)
Idea that it is difficult to quickly get an appointment for medical 
care
2.99 (1.21)
Easy access to doctor when necessary 3.31 (1.09)
Note: Standard Deviation are in ().
Symptoms
The frequency of each of the 69 different symptoms in the past year is summarizedin 
Table 6, as well as its impact on the participant’s abilities to carry out their everyday activities 
for those who reported experiencing the symptom. As we can see, the symptoms most 
commonly reported by patients are joint pain, fatigue, Raynaud’s, muscle pain, 
hardening/tightening of skin, difficulty sleeping, difficulty remember things and heartburn. 
Fatigue is the symptom reported as having more negative impact on the daily lives of 
patients.
Table 6
Presence, frequency and impact ofsymptoms
Symptom 
reported
Symptom reported
most of the 
time/always
Symptom impact 
reported moderate/ 
severe/ extremely 
severe
Hardening/Tightening of Skin 422 (89%) 244 (51%) 307 (68%)
Itchy Skin 494 (88%) 259 (46%) 218 (48.2)
Changes in Skin Color 465 (83%) 268 (48%) 181 (41%)
Dilated Blood Vessels on the Hands 427 (76%) 259 (46%) 211 (53%)
Dilated Blood Vessels on the Face 377 (67%) 214 (38%) 146 (38%)
Skin Rashes 382 (68%) 182 (32%) 136 (35%)
Hypersensitivity to the Sun 413 (73%) 232 (41%) 177 (43%)
Skin Infections due to Open Sores 341 (61%) 179 (32%) 180 (48%)
Calcium Deposits in the Skin 329 (58%) 204 (36%) 163 (49%)
Skin Pain 437 (78%) 264 (47%) 241 (59%)
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Joint Pain 448 (94%) 297 (63%) 375 (82%)
Swollen Joints 473 (84%) 282 (50%) 317 (73%)
Muscle Pain 422 (89%) 274 (58%) 351 (79%)
Tender Joints 476 (85%) 282 (50%) 299 (71%)
Difficulty Making a Fist 448 (80%) 311 (55%) 270 (67%)
Difficulty Fully Opening the Hand 418 (74%) 268 (48%) 223 (56%)
Difficulty Holding Objects 468 (83%) 264 (47%) 281 (67%)
Stiffness in the Hands 495 (88%) 343 (61%) 448 (80%)
Difficulty Turning on a Faucet 442 (79%) 235 (42%) 393 (70%)
Difficulty Self-Washing 378 (67%) 189 (34%) 351 (62%)
Difficulty Dressing 416 (74%) 194 (35%) 353 (63%)
Difficulty Walking 463 (82%) 265 (47%) 415 (74%)
Difficulty Climbing Stairs 467 (83%) 317 (56%) 422 (75%)
Difficulty Getting In/Out of a Car 428 (76%) 236 (42%) 368 (65%)
Dry Eyes 437 (78%) 284 (50%) 411 (73%)
Burning Sensation in the Eyes 401 (71%) 209 (37%) 379 (67%)
Gritty Sensation in the Eyes 415 (74%) 200 (36%) 347 (62%)
Dry Mouth 466 (83%) 311 (55%) 372 (76%)
Difficulty Chewing 389 (69%) 217 (39%) 373 (66%)
Difficulty Swallowing 442 (79%) 229 (41%) 364 (65%)
Painful Swallowing 345 (61%) 162 (29%) 344 (61%)
Choking While Eating Dry Foods 383 (68%) 188 (33%) 352 (63%)
Bad Taste in the Mouth at Night 415 (74%) 232 (41%) 303 (54%)
Heartburn 395 (87%) 201 (44%) 256 (67%)
Dental Caries or Decay 386 (69%) 205 (36%) 358 (64%)
Shortness of Breath 388 (86%) 170 (38%) 267 (69%)
Persistent Coughing 442 (79%) 239 (43%) 399 (71%)
Chest Pain 403 (72%) 203 (36%) 388 (69%)
Kidney Failure 292 (52%) 238 (42%) 415 (74%)
Rapid Heart Rate 407 (72%) 220 (39%) 352 (63%)
Irregular Heart Rate 396 (70%) 212 (38%) 359 (64%)
Fainting or Near Fainting 299 (53%) 145 (26%) 390 (69%)
Inflammation of the Liver 200 (36%) 139 (25%) 418 (74%)
Carpal Tunnel Syndrome 381 (68%) 221 (39%) 420 (75%)
Finger Ulcers 342 (61%) 216 (38%) 436 (77%)
Mouth Ulcers 281 (50%) 144 (26%) 377 (67%)
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Nose Ulcers 225 (40%) 141 (25%) 375 (67%)
Migraine Headaches 400 (71%) 174 (31%) 391 (69%)
Diarrhea 476 (85%) 206 (37%) 382 (68%)
Constipation 432 (77%) 224 (40%) 384 (68%)
Stool Incontinence 303 (54%) 176 (31%) 415 (74%)
Nausea 422 (75%) 178 (32%) 352 (63%)
Unwanted Weight Loss 303 (54%) 172 (31%) 386 (69%)
Vaginal Dryness 455 (81%) 349 (62%) 436 (77%)
Erectile Dysfunction 51 (73%) 25 (43%) 34 (97%)
Gland Swelling 270 (48%) 167 (30%) 364 (65%)
Thyroid Problems 239 (43%) 198 (35%) 398 (71%)
Blood Clots 184 (33%) 149 (27%) 402 (71%)
Recurrent Fever 271 (48%) 158 (28%) 386 (69%)
Fatigue 419 (93%) 290 (64%) 346 (84%)
Difficulty Sleeping 402 (88%) 202 (44%) 291 (72%)
Difficulty Concentrating 382 (85%) 130 (29%) 251 (63%)
Difficulty Remembering Things 394 (88%) 119 (26%) 224 (55%)
Medication Side Effects 422 (75%) 203 (36%) 370 (66%)
Raynaud’s 407 (90%) 289 (64%) 327 (80%)
Food Getting Stuck in the Mouth 361 (64%) 192 (34%) 373 (66%)
Difficulty Opening the Mouth 385 (68%) 230 (41%) 384 (68%)
Difficulty Brushing the Teeth 311 (55%) 198 (35%) 378 (67%)
Numbness in Feet or Lower Legs 463 (82%) 227 (40%) 390 (69%)
Note: Percentage related to the subjects that answer the item is in ().
Employment 
Table 7 describes the impact of scleroderma in the participants’ employment.Almost 
half the participants reported that scleroderma affects their ability to work somewhat, very 
much or extremely. A little more than half of the participants reported that scleroderma is not
been accommodated by the workplace neither understood in terms of the ability to perform 
job-related tasks. 
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Table 7
Frequency of the impact in employment 
Employment’ impact
Not at all/ a little bit Somewhat/ very 
much/ extremely
Affect the ability to work 194 (35%) 278 (49%)
Affect the ability to meet financial obligations 323 (57%) 135 (24%)
Been accommodated by the workplace 293 (52%) 159 (28%)
Been understood by the workplace in terms 
of the ability to perform job‐related tasks 292 (52%) 164 (29%)
Note: Percentage related to the subjects that answer the item is in ().
Depression and anxiety
The assembly of two items that constitute the PHQ-2 assessed depression severity 
measuring anhedonia and dysphoria, respectively. The results are in Table 8 and show that 
38% of participants show sensitivity to severe depression.
Table 8
Frequency of PHQ-2 items
Not at all Several 
days
More than 
half the days
Nearly 
every day
Little interest or pleasure in doing 
things
114 (26%) 173 (39%) 68 (16%) 85 (19%)
Feeling down, depressed, or 
hopeless
128 (29%) 177 (40%) 55 (13%) 80 (18%)
Note. Percentage related to the subjects that answer the item is in ().
The assessment of anxiety symptoms is calculated using GAD-2. The results of these 
items are in Table 9 and the application of cut-off criteria show that 32% of participants 
reported symptoms of generalized anxiety symptoms.
Table 9
Frequency of GAD-2 items
Not at all Several 
days
More than 
half the 
days
Nearly 
every day
Feeling nervous, anxious, or on edge 132 (30%) 204 (46%) 61 (14%) 45 (19%)
Not being able to stop or control 
worrying
174 (39%) 175 (40%) 51 (12%) 42 (10%)
Note. Percentage related to the subjects that answer the item are in ().
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The assessment of the general social anxiety symptoms (social phobia) was made 
using three items of Mini-SPIN. The results of these items are in Table 10. Using the cut –off 
of the instrument 30% of participants reported social phobia symptoms.
Table 10
Frequency of tree Mini-SPIN items
Not at 
all
A little 
bit
Somewhat Very 
much
Extremely
Fear of embarrassment causes 
avoid to do things or speak to 
people
205 
(47%)
111 
(25%)
46
(11%)
48 
(11%)
30
(7%)
Avoid activities in which is the 
centre of attention
164
(37%)
88
(20%)
63
(14%)
85
(19%)
42
(10%)
Being embarrassed or looking 
stupid are among the worse fears
191
(43%)
96
(22%)
53
(12%)
65
(15%)
38
(9%)
Note: Percentage related to the subjects that answer the item are in ().
Body Image
Assessing body image, 34% of participants show body image disturbance. Table 11 
describes the participants’ concerns about changes in the body image, due to scleroderma. 
Table 11
Frequency of Body Image Concerns 
Never or a 
little
Moderate, a lot 
or extremely
Preoccupation with parts of the body considered not attractive 190 (44%) 247 (57%)
Impairment in social, occupational or other important areas of 
functioning, due to changes caused by scleroderma
243 (56%) 195 (45%)
Avoidance of things due to the disfigurement by scleroderma 290 (66%) 147 (34%)
Note: Percentage related to the subjects that answer the item are in ().
Illness Perception
Table 12 summarizes the results of the means obtained in the dimensions of the Brief 
IPQ. Results show that participants are aware of the chronicity of the disease.Regarding the 
illness concern, participants report a high degree of concern with scleroderma. Participants 
are considerably emotionally affected by the illness. Regarding illness identity and 
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consequences, participants reported that scleroderma is associated with several symptoms, 
which considerably affects their lives.In general the participants believe considerably in the 
effectiveness of treatments and in the fact that they have some illness personal control. The 
subscale with the lowest score was coherence, showing that participants do not understand 
scleroderma.
Table 12
Means of Illness Perception
Subscales Mean
Consequences 6.22 (2.74)
Timeline 9.33 (1.8)
Personal Control 5.79 (2.44)
Treatment Control 5.03 (2.41)
Identity 6.17 (2.4)
Illness concern 7.19 (2.53)
Coherence 3.97 (2.54)
Emotional Representation 6.58 (2.74)
Note: Standard Deviation are in ().
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Inferential Statistics
The correlation among the variables age, years with diagnosis, frequency of the 
symptoms, impact of the symptoms, body image, depression, anxiety, social phobia, illness 
perception and satisfaction with medical care is presented in table 13. 
Table13
Spearman correlations test between variables
Variable 1 2 3 4 5 6 7 8 9
1. Age
2. Years with 
diagnosis
2.11**
3. Frequency 
of Symptoms .15** .09*
4. Impact of 
Symptoms
-.90* 0 .10*
5. Body Image -.13** .07 .04 .38**
6. Depression -.09* -.06 -.28** .31** .13**
7. Anxiety -.07 .04 0 .21** .34** .08
8. Social 
Phobia
-.01 .01 .03 .25** .53** .10 * .43**
9. Illness 
Perception
.01 .07 .22** .26** .37** -.01 .32** .36**
10. 
Satisfaction 
with medical 
care
-.07 .15** .01 0 -.03 -.06 -.03 -.01 .10
Note: *p<.05; **p<.01
The years with diagnosis is positively correlated with the age (r= 2.11, p<.01). Older 
participants have more years with diagnosis.
The frequency of the symptoms is positively correlated with the age (r= .15, p<.01) 
and with the years with diagnosis (r= .09, p<.05). Older participants and with more years with 
diagnosis reported higherfrequency of the symptoms of scleroderma.
The impact of symptoms is negatively correlated with age (r= -.9, p<.05) and 
positively correlated with the frequency of the symptoms (r= .1, p<.05). Younger participants 
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reported more impact of symptoms. Participants who reported more frequency of symptoms, 
also reported more impact of the symptoms. 
Body image is negatively correlated with age (r= -.13, p<.01) and positively correlated
with impact of symptoms (r= .38, p<.01). Younger participant reported worse body image. 
Participants who reported more impact of the symptoms also reported worse body image. 
Depression is negatively correlated with age (r= -.09, p<.05) and with frequency of 
symptoms (r= -.28, p<.01), and is positively correlated with the impact of symptoms (r= .31, 
p<.01) and with body image (r= .13, p<.01). Younger participants and participants with less 
frequency of symptoms reported more symptoms of depression. Participants with more 
impact of symptoms and participants with worse body image reported more symptoms of 
depression. 
Anxiety is positively correlated with the impact of symptoms (r= .21, p<.01)  and with 
body image (r= .34, p<.01). Participants with more impact of symptoms and participants with 
worse body image reported more symptoms of anxiety.
Social phobia is positively correlated with the impact of symptoms (r= .25, p<.01), with 
body image (r= .53, p<.01), with depression (r= .1, p<.05) and with anxiety (rp= .43, p<.01). 
Participants who reported more impact of the symptoms, participants with worse body image, 
participants with depression and participants with anxiety, reported more symptoms of social 
phobia. 
Illness perception is positively correlated with frequency of symptoms (r= .22, p<.01), 
with impact of symptoms (r= .26, p<.01), with body image (r= .37, p<.01), with anxiety (r= .32, 
p<.01) and with social phobia (r= .36, p<.01). Participants who reported more frequency of 
symptoms, more impact of symptoms, with worse body image, with anxiety and with social 
phobia, perceive illness as more threatening. 
Satisfaction with medical care is positively correlated with years with diagnosis (r= 
.15, p<.01). Participants with more years with diagnosis are more satisfied with the medical 
care.                
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Hypotheses testing
Hypothesis 1:
Participants with depressive symptoms have a worse body image, report more 
symptoms of pain, more impact of pain, more symptoms of fatigue, more symptoms 
associated with the disease, more impact of these symptoms, have a more negative illness
perception and are more dissatisfied with medical care they receive.
Table 14
Results of t test for independent samples comparing participants with and without depression
With Depression
Mean (SD)
Without Depression
Mean (SD)
t (df)
Body image 8.87 (3.35) 6.51 (2.73) -7.91 (422) ***
Frequency of symptoms of pain 7.18 (2.27) 6.71 (2.2) -2.07  (392) *
Impact of symptoms of pain 7.3 (2.35) 6.46 (2.43) -3.59  (438) ***
Fatigue 2.99 (1.18) 2.54 (1.17) -3.68  (399) ***
Frequency of symptoms 39.41 (20.15) 38.99 (17.48) -.23  (438), n.s.
Impact of symptoms 41.79 (11.67) 36.7 (12.97) -4.15  (438) ***
Illness perception 52.02 (9.74) 44.77 (11.48) -6.71  (422) ***
Medical care 62.9 (108.43) 50.51 (91.28) -1.21  (389), n.s.
Note: * p<.05; ***p<.001
As we can see, participants with depression report worse body image, more 
symptoms and impact of pain, more fatigue, more impact of symptoms of the disease and 
perceive illness as more threatening. There were no differences between group on frequency 
of symptoms and medical care
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Hypothesis 2:
Participants with anxiety symptoms have a worse body image, report more symptoms 
of pain, more impact of pain, more symptoms of fatigue, more symptoms associated with the 
disease, more impact of these symptoms, have a more negative illness perception and are 
more dissatisfied with medical care they receive.
Table 15
Results of ttest for independent samples comparing participants with and without anxiety
With Anxiety
Mean (SD)
Without Anxiety
Mean (SD)
t 
Body Image 8.83 (3.6) 6.81 (2.83) -6.06 (424) ***
Frequency of symptoms of pain 7.1 (2.33) 6.86 (2.19) -.93 (393) , n.s.
Impact of pain symptoms 7.46 (2.24) 6.52 (2.44) -3.65 (439) ***
Fatigue 2.85 (1.25) 2.67 (1.3) -1.3 (400) , n.s.
Frequency of symptoms 38.93 (19.89) 39.44 (17.93) -.07 (439) , n.s.
Impact of symptoms 38.93 (19.89) 39.44 (17.93) -.26 (439) , n.s.
Illness perception 52.75 (10.49) 45.83 (11) -5.82 (423) ***
Medical care 48.5 (87.8) 56.16 (99.57) -.7 (391) , n.s.
Note: *** p<.001
Participants with anxiety have a worse body image, reported more impact of 
symptoms of pain and perceive illness as more threatening, but are not different from the 
ones without anxiety in the other variables.    
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Hypothesis 3:
Participants with social phobia symptoms have a worse body image, report more 
symptoms and impact of pain, more symptoms of fatigue, more symptoms associated with 
the disease, more impact of these symptoms, have a more negative illness perception and 
are more dissatisfied with the medical care they receive.
Table 16
Results of t test for independent samples between participants with and without social phobia
and other variables
With Social 
Phobia
Mean (SD)
Without Social 
Phobia
Mean (SD)
t 
Body image 9.34 (3.48) 6.54 (2.64) -9.05 (421)***
Frequency of symptoms of pain 7.29 (2.32) 6.73 (2.17) -2.29 (393) *
Impact of symptoms of pain 7.26 (2.4) 6.57 (2.41) -2.73 (437) **
Fatigue 2.96 (1.2) 2.61 (1.16) -2.71 (397) **
Frequency of symptoms 39.27 (21.27) 39.21 (17.12) -.03 (437) , n.s.
Impact of symptoms 41.98 (12.15) 37.20 (12.72) -3.67 (437) ***
Illness perception 52.39 (10.18) 45.48 (11.04) -6.04 (421) ***
Medical care 56.2 (96.1) 54.9 (99.38) -.12 (389) , n.s.
Note:*p<.05; ** p<.01; *** p<.001
Participants with social phobia have significantly worse body image, reported more 
symptoms of pain, more impact of symptoms of pain, more fatigue, more impact of 
symptoms of the disease and perceive illness as more threatening.    
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Discussion
This study aims mainly to characterize the most common symptoms of scleroderma, 
the impact felt by patients, assess satisfaction with medical care, psychological symptoms 
and illness perception. Another objective is to understand the correlation between the 
variables: age, years with diagnosis, frequency of the symptoms, impact of the symptoms, 
body image, depression, anxiety, social phobia, illness perception and satisfaction with 
medical care. And finally the study aims to evaluate if there are differences in the 
dimensions: body image, frequency of symptoms of pain, impact of symptoms of pain, 
fatigue, frequency of symptoms related to scleroderma, impact of this symptoms, illness 
perception and medical care,when comparingpatients with andwithout depressive symptoms;
patients with andwithout symptoms of anxiety and patients with andwithout symptoms of 
social phobia.
The five most common symptoms reported by patients were: joint pain (94%), fatigue 
(93%), Raynaud's (90%), muscle pain (89%) and hardening / tightening skin (89%). These
results were approximated to the Canadian study (Taillefer et al, 2010). Regarding the 
impact of symptoms, the five symptoms with the greatest impact were: fatigue (84%), joint 
pain (82%), Raynaud's (80%), Stiffness in the hands (80%) and muscle pain (79%). Also in 
this case the results are similar to those of Canada (Tailleffer et al., 2010).
Only 19% of patients were able to get the diagnosis of scleroderma with the first 
doctor consulted. This could be explained by the difficulty of diagnosis of scleroderma. Often 
the symptoms of scleroderma tend to be confused with symptoms of other diseases for a 
long time, moreover, as already stated, this disease remains unknown to many health 
professionals.In general, participants showed satisfaction with the medical care they receive
and this result is similar to that obtained by Taillefer et al. (2010).Participants with more years 
of diagnosis revealed to be more satisfied with the medical care they receive.This result can 
be explained because there is less uncertainty about the diagnosis when compared with 
those diagnosed more recently.There were no differences in satisfaction with medical care 
among people with and without depression, or with and without anxiety or with and without 
social phobia. We also found no significant correlations between satisfaction with medical 
care and age, or frequency or impact of symptoms.Further studies must be made to 
determine which variables are related to satisfaction with medical care.
Almost a third of participants reported that they do not have access to all medical care 
due to its cost. Scleroderma involves many treatments and, depending on the health system 
of each country, not all treatments are free or reimbursed to patients. This data can be even 
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more relevant with the fact that almost half the participants showed that scleroderma affects 
the ability to work.
Regarding depression, the results suggest that 38% of participants have sensitivity for 
severe depression. This finding is consistent with the fact that depression is quite common in 
scleroderma (Benrud-Larson et al, 2002).The results suggest that younger participants 
reported more symptoms of depression andthis finding supports the conclusion of Roca 
(1996) that younger patients have more depressive symptoms.An interesting relation to 
depression, is that participants who reported less frequent symptoms have fewer symptoms 
of depression, however there are no differences between participants with and without 
depression (a measure that uses a cut-off value) in the frequency of symptoms reported. 
Those who have more impact report more symptoms of depression and there are differences 
between participants with and without depression in the account of the impact of symptoms. 
The interpretation of these data suggests that the impact perceived by the participants is 
important in the existence of depressive symptoms and not the frequency of symptoms, or it 
can be that subjects with more depressive humor report higher impact of the symptoms.
About one third of participants (34%) have body image disturbance. In particular, 84% 
of participants report experiencing preoccupation with body image due to scleroderma. This 
result is approximate to that obtained by Taillefer et al. (2010) which was 77%. Participants 
who reported worse body image reported more symptoms of depression, and there are 
differences in participants with and without depression in body image, since those who have 
depression have poorer body image.This finding is not surprising since scleroderma involves 
many physical changes visible in parts of the body, and depression has been reported as a 
common problem in people affected with various types of deformation (Thompson, 2001). 
The results indicate that in relation to anxiety, 32% of participants reported symptoms
of generalized anxiety. This finding is consistent with Thompson (2001) which says that 
anxiety is very prevalent in people with some type of physical disfigurement; in particular, 
anxiety is common in scleroderma patients (Legendre et al., 2005). Participants with worse 
body image reported more symptoms of anxiety, and there are differences between 
participants with and without anxiety, participants with anxiety have a worse body image. We 
found no relationship between the frequency of symptoms of scleroderma and anxiety. This 
finding is consistent with (Baubet, 2011) and can be explained by the fact that the emotional 
response is more related to the meaning given to the disease thanto disease severity.
Regarding the impact of the symptoms of pain, there are differences between 
participants with and without anxiety, with the first report more symptoms of pain.Baubet
(2011) also associated symptoms of pain, a characteristic of scleroderma, with anxiety.
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The symptoms of social phobia are reported by30% of the participants. More than half 
of participants reported that they avoid activities which they are the center of attention; this 
finding is consistent with Taillefer (2010). Participants with worse body image reported more 
symptoms of social phobia and there are differences between participants with and without 
social phobia: those with social phobia reported worse body image.According to Thompson 
(2001) people with disfigurement tend to avoid social situations.People with social phobia 
reported more frequency and impact of symptoms of pain and more impact of scleroderma 
symptoms than those without social phobia.
Regarding the illness perception, participants report a high degree of concern with 
scleroderma. This can be explained by the severity of the symptoms of scleroderma and also 
by its unpredictability and unfamiliarity.In fact, participants reported that they do not 
understand the disease, consistent with Richards et al. (2003).This idea can be supported by 
other results of this study that indicate that there is a correlation between the frequency and 
impact of symptoms of scleroderma with the perception of the disease.According to Richards 
et al. (2003) Illness perception is related to emotional disturbance. In this study, illness 
perception is positive correlated with anxiety and social phobia, however there is no 
significant correlation with depression and this is a puzzling result.We found that people 
which have perceived greater threat of disease, reported worse body image. This can be 
explained by another result, in which the participants reveal that the symptoms are seriously 
affecting their life.
Finally, participants who reported more symptoms, also reported higher impact of 
symptoms. Perhaps because of the fact that people who experience a large number of 
symptoms, may perceive the impact of symptoms as more severe and more affecting their 
quality of life.
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Limitations and Future Studies
There were several limitations identified during the implementation of this study.
The time available to develop the project was too short, given the extent of it. It took a 
long time to coordinate contacts with all institutions concerned, particularly Portuguese 
hospitals and international associations. Thus, we could not include in this study all data 
collected since the collection still running. Despite this limitation and the extension of the 
survey, the number of participants exceeded our initial expectations.
Once that had to be made several translations of survey, it was not available online 
simultaneously for all countries, due to this factor and also because the number of patients is 
not the same in all countries (the number of the population is very different in the countries 
involved), the number of participants from various countries was not proportional.
It would have been interesting to have included the social support variable in this 
study.
The aim of this study was not to evaluate predictors of psychological adjustment, but 
in the future it will be important to evaluate the contribution of some clinical variables for the 
depression and anxiety symptoms. Another alternative would be to evaluate the way 
depressive symptoms influence the report of symptoms. 
Analysis should consider the different types of scleroderma, because there are many 
differences in symptoms and severity of for instance a limited type and diffuse type. Are there 
differences in adaptation to the disease between different types of scleroderma? This is a 
question which remains for future studies.
We intend to continue research in this area so far largely neglected.The next step is 
to enter the remaining data in the study, including the following countries: Germany, Belgium 
and Switzerland. 
We maintain contact with the Canadian team and also with a Dutch team that did the 
same study of Dutch patients and we as a project to establish a cooperation plan to compare 
the data.
Psychosocial Characterization, Symptoms and Illness Perception in Scleroderma Patients: 
an international study
41
References
Abad, V.C., Sarinas, P.S.A., &Guilleminault, C. (2008). Sleep and rheumatologic disorders. 
Sleep Medicine Reviews, 12, 211-228. 
Assassi, S., del Junco, D., Sutter, K., McNearney, T.A., Reveille, J.D., Karvanas, A.,… 
Gourh, P. (2009). Clinical and Genetic Factors Predictive of Mortality in Early Systemic 
Sclerosis. Arthritis Rheumatism, 61, 1403-1411. 
Baubet, T., Ranque, B., Taïeb, O., Bérezné, A., Bricou, O., Mehallel, S., ... Mouton, L. 
(2011). Mood and anxiety disorders in systemic sclerosis patients. Presse Medicale, 40, 
111-119. 
Benrud-Larson, L. M., Haythornthwaite, J.A., Heinberg, L.J., Boling, C., Reed, J., White, B., 
& Wigley, F.M. (2002). The impact of pain and symptoms of depression in scleroderma. 
Pain, 95, 267-275. 
Benrud-Larson, L.M., Heinberg, L.J., Boling, C., Reed, J., White, B., Wigley, F.M. &
Haythornthwaite, J.A. (2003). Body Image Dissatisfaction Among Women With 
Scleroderma: Extent and Relationship to Psychosocial Function. Health Psychology, 22, 
130-139. 
Beutel, M.E., Schulz, H. (2011). Epidemiologie psychisch komorbider störungen bei 
chronisch körperlichen erkrankungen. Bundesgesundheltsbl, 54, 15-21.
Broadbent, E., Petrie, K.J., Main, J., & Weinman, J. (2006). The Brief Illness Perception 
Questionnaire (BIPQ).Journal of Psychosomatic Research, 60,631-637. 
Brown, K.M., Middaugh, S.J., Haythornthwaite, J.A.,& Bielory, L. (2001). The effects of 
stress, anxiety, and outdoor temperature on the frequency and severity of Raynaud’s 
attacks: the Raynaud’s treatment study. Journal of Behavioral Medicine, 24, 137-153. 
Cash, T.F., Phillips, K.A., Santos, M.T. & Hrabosky, J.I. (2004). Measuring “negative body 
image”: validation of the Body Image Disturbance Questionnaire in a nonclinical 
population. Body Image, 1, 363-372. 
Chifflot, H., Fautrel, B., Sordet, C., Chatelus, E., & Sibilia, J. (2008). Incidence and 
prevalence of systemic sclerosis: a systematic literature review. Elsevier Inc. Seminars 
in Arthritis and Rheumatism, 37, 223-235. 
Christmann, R.B. & Silver, R.M. (2010). Gastroesophageal reflux incites intersticial lung
disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment 
evidence. Seminars in Arthritis and Rheumatism, 40, 241-249. 
Chung, L. & Fiorentino, D. (2006). Digital ulcers in patients with systemic sclerosis. 
Autoimmunity Reviews, 5, 125-128. 
Psychosocial Characterization, Symptoms and Illness Perception in Scleroderma Patients: 
an international study
42
Clements, P.J., Lachenbruch, P.A., Ng, S.C., Simmons, M., Sterz, M. & Furst, D. E. (1990). 
Skin score: a semiquantitative measure of cutaneous involvement that improves 
prediction of prognosis in systemic sclerosis. Arthritis & Rheumatism, 33, 1256-1263. 
Coelho, L.F.L., Oliveira, J.G., Kroon, E.G. (2008). Interferons and scleroderma – A new clue 
to understanding the pathogenesis of scleroderma? Immunology Letters, 118, 110-115.
Connor, K.M., Kobak, K.A., Churchill, L.E., Katzelnick, D. & Davidson, J.R.T. (2001). Mini-
SPIN: a brief screening assessment for generalized social anxiety disorder. Depression 
and Anxiety, 14, 137-140. 
Danieli, E., Airò, P., Bettoni, L., Cinquini, M., Antonioli, C.M., Cavazzana, I., ... Cattaneo, R. 
(2005). Health-related quality of life measured by the short form 36 (SF-36) in systemic 
sclerosis: correlations with indexes of disease activity and severity, disability, and 
depressive symptoms. Clinical Rheumatology, 24, 48-54. 
Grosso, S., Fioravante, A., Biasi, G., Conversano, E., Marcolongo, R., Morgese, G. & 
Balestri, P. (2003). Linear scleroderma associated with progressive brain atrophy. Brain 
and Development, 25, 57-61. 
Gupta, R., & Thabah, M.M. (2007). Management of interstitial lung disease in scleroderma. 
Indian Journal of Rheumatology, 2, 23-30. 
Hansdottir, I., Malcarne, V.L., Furst, D.E., Weisman, M.H. & Clements, P.J. (2004). 
Relationships of positive and negative affect to coping and functional outcomes in 
systemic sclerosis. Cognitive Therapy and Research, 28, 593-610. 
Haythornthwaite, J.A., Heinberg, L.J. & McGuire, L. (2003). Psychologic factors in 
scleroderma. Rheumatic Disease Clinics of North America, 29, 427-439. 
Hinchcliff, M. & Varga, J. (2008). Systemic Sclerosis/Scleroderma: a Treatable Multisystem 
Disease. American Academy of Family Physicians, 78, 961-969. 
Kahaleh, M.B. (2004). Raynaud phenomenon and the vascular disease in scleroderma. 
Current Opinion in Rheumatology, 16, 718-722. 
Kasapçopur, O., Ozkan, H.C. & Tuysuz, B. (2003). Linear scleroderma em coup de sabre 
and brain calcification: is there a pathogenic relationship? Journal of Rheumatology, 30, 
2724-2725. 
Kissin, E.Y., Schiller, A.M., Gelbard, R.B., Anderson, J.J., Falanga, V., Simms, R.W., ... 
Merkel, P.A. (2006). Durometry for the assessment of skin disease in systemic sclerosis. 
Arthritis Care & Research, 55, 603-609. 
Knafo, R., Jewett, L.R., Bassel, M., & Thombs, B.D. (2010). Sexual Function in women with 
systemic sclerosis: comment on the article by Schouffoer et al. Arthritis Care & 
Research, 62, 1200-1202. 
Psychosocial Characterization, Symptoms and Illness Perception in Scleroderma Patients: 
an international study
43
Kobayashi-Gutierrez, A., Martinez-Bonilla, G., Bernard-Medina, A.G., Troyo-Sanroman, R., 
González-Díaz, V., Castro-Contreras, E., ... Torres-Mendoza, B.M. (2009). Depression 
and its correlation with in patients pain in the rheumatology service of a Mexican 
teaching hospital. Rheumatology International, 29, 1169-1175. 
Kroenke, K. & Spitzer, R.L. (2002). The PHQ-9 a new depression diagnostic and severity 
measure, Psychiatric Annals, 32, 1-7. 
Kroenke, K., Spitzer, R.L., Williams, J.B.W., Monahan, P.O. & Lowe, B. (2007). Anxiety 
disorders in primary care: prevalence, impairment, comorbidity, and detection. Annals of 
Internal Medicine, 146, 317-325. 
Le Pavec, J., Launay, D., Mathai, S.C., Hassoun, P.M. & Humbert, M. (2011). Scleroderma 
Lung Disease. Clinical Reviews in Allergy and Immunology, 40, 104-116.
Legendre, C., Allanore, Y., Ferrand, I., & Kahan, A. (2005). Evaluation of depression and 
anxiety in patients with systemic sclerosis. Joint Bone Spine, 72, 408-411. 
Li, Q., Sahhar, J. & Littlejohn, G. (2008). Red Flags in Scleroderma. Australian Family 
Physician, 37, 831-834.
Malcarne, V.L., Hansdottir, I., Greenbergs, H.L., Clements, P.J. & Weisman, M.H. (1999). 
Cognitive Therapy and Research, 23, 197-208. 
Marshall, G.N. & Hays, R.D. (1994). The patient satisfaction questionnaire short-form (PSQ-
18).Santa Monica, CA: Rand Corporation.
Martins, C. (2011). Manual de análise de dados quantitativos com resurso ao IBM SPSS: 
saber decidir, fazer, interpretar e redigir. Braga: Psiquilibrios Edições.
Merkel, P. A., Herlyn, K., Martin, R. W., Anderson, J. J., Mayes, M. D., Bell, P., ... Wigley, 
F.M. (2002). Measuring disease activity and functional status in patients with 
scleroderma and raynaud’s phenomenon. Arthritis & Rheumatism, 46, 2410-2420. 
Morell-Dubois, S., Condette-Wojtasik, G., Clerson, P., Berezné, A., Launay. D., Lambert, M., 
... Hachulla, E. (2011). Plaintesetbesoins des patients atteints de 
sclérodermiesystémique: unemeilleureconnaissanceafin d’améliorer le suivi. La Revue 
de Médecine Interne, 32, 537-543. 
Nadashkevich, O., Davis, P., & Fritzler, M. J. (2004). A proposal of criteria for classification of 
systemic sclerosis. Medical Science Monitor, 10, 615-621. 
Olsen, N.J., King, L.E. & Park, J.H. (1996). Muscle Abnormalities in scleroderma. Rheumatic 
Disease Clinics of North America, 22, 783-796. 
Ostojic, P. & Damjanov, N. (2007). The impact of depression, microvasculopathy, and 
fibrosis on development of erectile dysfunction in men with systemic sclerosis. Clinical 
Rheumatology, 26, 1671-1674. 
Psychosocial Characterization, Symptoms and Illness Perception in Scleroderma Patients: 
an international study
44
Ostojic, P., Zivojinovic, S., Reza, T. & Damjanov, N. (2010). Symptoms of depression and 
anxiety in Serbian patients with systemic sclerosis: impact of disease severity and 
socioeconomic factors. Modern Rheumatology, 20, 353-357. 
Ostojic, P.S. & Damjanov, N.S. (2006). The scleroderma assessment questionnaire (SAQ). Z 
Rheumatol, 65, 168-175. 
Pizzo, G., Scardina, G.A. & Messina, P. (2003).Effects of a nonsurgical exercice program on 
the decreased mouth opening in patients with systemic scleroderma. Clinical Oral 
Investigations, 8, 40.
Plastiras, S.C., Tzivras, M. & Vlachoyiannopoulos, G. (2007). Severe gastrointestinal 
involvement in systemic sclerosis. Clin Rheumatol, 26, 1025-1026. 
Poormoghim, H., Lucas, M., Fertig, N. & Medsger, T.A. (2000). Systemic Sclerosis Sine 
Scleroderma. Arthritis & Rheumatism, 43, 444-451. 
Richards, H.L., Herrick, A.L., Griffin, K., Gwilliam, P.D.H. & Fortune, D.G. 
(2004).Psychological adjustment to systemic sclerosis – exploring the association of 
disease factors, functional ability, body related attitudes and fear of negative avaluation. 
Psychology, Health & Medicine, 9, 29-39. 
Richards, H.L., Herrick, A.L., Griffin, K., Gwilliam, P.D.H., Loukes, J. & Fortune, D.G. (2003). 
Systemic Sclerosis: Patients’ Perceptions of their Condition. Arthritis & Rheumatism 
(Arthritis Care Research),49, 689-696
Roca, R.P., Wigley, F.M. & White, B. (1996). Depressive Symptoms Associated with 
Scleroderma. Arthritis & Rheumatism, 39, 1035-1040. 
Roth, M.D., Tseng, C., Clements, P.J., Furst, D.E., Tashkin, D.P., Goldin, J.G., ...  Elashoff, 
R.M., (2011). Predicting treatment outcomes and responder subsets in scleroderma-
related intersticial lung disease. Arthritis & Rheumatism, 63, 2797-2808. 
Ruzek, M.C., Jha, S., Ledbetter, S., Richards, S.M. & Garman, R.D. (2004). A modified 
model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major 
aspects of the human disease. Arthritis & Rheumatism, 50, 1319-1331. 
Sandqvist, G., Scheja, A. & Hesselstrand, R. (2010). Pain, fatigue and hand function closely 
correlated to work ability and employment status in systemic sclerosis. Oxford Journals, 
49, 1739-1746. 
Sandusky, S.B., McGuire, L., Smith, M.T., Wigley, F.M., & Haythornthwaite, J.A. (2009). 
Fatigue: an overlooked determinant of physical function in scleroderma. Rheumatology, 
48, 165-169.
Steen, V.D., &Medsger, T.A. (2001). Improvement in skin thickening in systemic sclerosis 
associated with improved survival. Arthritis & Rheumatism, 44, 2828-2835. 
Swain, M.G. (2000). Fatigue in chronic disease. Clinical Science, 99, 1-8. 
Psychosocial Characterization, Symptoms and Illness Perception in Scleroderma Patients: 
an international study
45
Taillefer, S.S., Bernstein, J., Schieir, O., Buzza, R., Hudson, M., Scleroderma Society of 
Canada, … Thombs, B. (2010). Canadian scleroderma patient survey of health concerns 
and research priorities: an iniciative of the scleroderma society of Canada and the 
Canadian scleroderma research group. Unpublished manuscript.
Thombs, B.D., Fuss, S., Hudson, M., Schieir, O., Taillefer, S.S., Fogel, J., ... Canadian 
Scleroderma Research Group (2008). High rates of depressive symptoms among 
patients with systemic sclerosis are not explained by differential reporting of somatic 
symptoms. Arthritis & Rheumatism (Arthritis Care & Research), 59, 431-437. 
Thombs, B. D., Jewett, L. R., Assassi, S., Baron, M., Maia, A. C., El-Baalbaki, G., ... & 
Khanna, D. (in press). New directions for patient-centered care in scleroderma: the 
scleroderma patient-centered intervention network (SPIN).Clinical and Experimental 
Rheumatology.
Thompson, A. (2001). Adjusting to disfigurement: processes involved in dealing with being 
visibly different. Clinical Psychology Review, 21, 663-682. 
Varga, J. (2008). Systemic sclerosis: an update. Buletinl of the NYU Hospital for Joint 
Diseases, 66, 198-202. 
Vilella, C.T., Aznar, C.P.S. & Julià, L.G. (2010). El fenómeno de Raynaud. Medicina Clínica, 
134, 470. 
Zulian, F., Athreya, B. H., Laxer, R., Nelson, A. M., de Oliveira, S. K. F., Punaro, M. G., ... 
Harper, J. (2006). Juvenile localized scleroderma: clinical and epidemiological features 
in 750 children. An international study. Rheumatology, 45, 614-620.
